Abstract | PURPOSE: METHODS: A study of our experience with paricalcitol was conducted in normal clinical practice in patients over 18 years diagnosed with grade 3 or 4 chronic kidney disease. Patients were periodically evaluated every 3 months. The primary endpoint of effectiveness was to obtain two consecutive decreases of ≥30% in iPTH with respect to baseline values. The secondary endpoints were fulfilment of the objectives in accordance with the Spanish Society of Nephrology (SEN) and Kidney Disease Outcomes Quality Initiative (K/DOQI) guidelines, as well as the relationship between the effectiveness of the treatment and different patient variables. Safety was studied by means of hypercalcaemia events. RESULTS: The primary study endpoint was achieved in 54.3% of patients. In addition, another 16.3% of patients had reduced iPTH by more than 30% at the 3rd visit. Therefore, 70.6% of patients reduced their iPTH levels by more than 30% in 6 months. The relationship between treatment success and both glomerular filtration rate and body mass index was significant. There were few adverse events, although hypercalcaemia was found in 5.4% of patients. CONCLUSIONS:
|
Authors | José Gregorio Hervás Sánchez, María Dolores Prados Garrido, Aurora Polo Moyano, Sebastian Cerezo Morales |
Journal | Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia
(Nefrologia)
Vol. 31
Issue 6
Pg. 697-706
( 2011)
ISSN: 1989-2284 [Electronic] Spain |
PMID | 22130286
(Publication Type: Journal Article)
|
Chemical References |
- Ergocalciferols
- Parathyroid Hormone
- Phosphorus
- paricalcitol
- Calcium
|
Topics |
- Aged
- Aged, 80 and over
- Body Mass Index
- Calcium
(blood)
- Chronic Disease
- Diabetic Nephropathies
(blood, complications)
- Dose-Response Relationship, Drug
- Drug Evaluation
- Endpoint Determination
- Ergocalciferols
(administration & dosage, therapeutic use)
- Female
- Follow-Up Studies
- Glomerular Filtration Rate
- Humans
- Hypercalcemia
(etiology, prevention & control)
- Hyperparathyroidism, Secondary
(blood, drug therapy, etiology)
- Kidney Diseases
(complications)
- Male
- Middle Aged
- Parathyroid Hormone
(blood)
- Phosphorus
(blood)
- Retrospective Studies
- Severity of Illness Index
- Treatment Outcome
|